131I-tositumomab therapy as initial treatment for follicular lymphoma

New England Journal of Medicine

Volumn 352, Issue 5, 2005, Pages 441-449

  Kaminski, Mark S ^a,f   Tuck, Melissa ^a   Estes, Judith ^a   Kolstad, Arne ^c   Ross, Charles W ^b   Zasadny, Kenneth ^b   Regan, Denise ^b   Kison, Paul ^b   Fisher, Susan ^b   Kroll, Stewart ^d   Wahl, Richard L ^e  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d GLAXOSMITHKLINE   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOPOIETIC GROWTH FACTOR; PROTEIN BCL 2; TOSITUMOMAB I 131; CD20 ANTIGEN; IODINE 131 ANTI B1 ANTIBODY; IODINE-131 ANTI-B1 ANTIBODY; MONOCLONAL ANTIBODY; THYROTROPIN;

ADULT; AGED; ARTHRALGIA; ARTICLE; B LYMPHOCYTE; CANCER REGRESSION; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DOSE RESPONSE; DOSIMETRY; FEBRILE NEUTROPENIA; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; HEADACHE; HEMATOLOGIC DISEASE; HEMOGLOBIN DETERMINATION; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; LYMPHOCYTE DEPLETION; MAJOR CLINICAL STUDY; MALE; MYALGIA; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; NEUTROPHIL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RADIATION DOSE; SIDE EFFECT; SURVIVAL RATE; THROMBOCYTOPENIA; THYROID FUNCTION; TREATMENT OUTCOME; BLOOD; BONE MARROW EXAMINATION; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFECT; GENE REARRANGEMENT; GENETICS; IMMUNOLOGY; LEUKOCYTE COUNT; MIDDLE AGED; PHASE 2 CLINICAL TRIAL; PROTO ONCOGENE; RADIOIMMUNOTHERAPY; RADIOMETRY; REMISSION; SURVIVAL;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; B-LYMPHOCYTES; BONE MARROW EXAMINATION; DISEASE-FREE SURVIVAL; FEMALE; GENE REARRANGEMENT; GENES, BCL-2; HUMANS; LEUKOCYTE COUNT; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; RADIOIMMUNOTHERAPY; RADIOMETRY; REMISSION INDUCTION; SURVIVAL ANALYSIS; THYROTROPIN;

EID: 12944275472     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa041511     Document Type: Article

References (35)

1. Mac Manus MP, Hoppe RT. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol 1996;14:1282-90.
2. Reddy S, Saxena VS, Pellettiere EV, Hendrickson FR. Stage I and II non-Hodgkin's lymphomas: long-term results of radiation therapy. Int J Radiat Oncol Biol Phys 1989;16:687-92.
3. Buchsbaum DJ, Wahl RL, Normolle DP, Kaminski MS. Therapy with unlabeled and 131I-labeled pan-B-cell monoclonal antibodies in nude mice bearing Raji Burkitt's lymphoma xenografts. Cancer Res 1992;52:6476-81.
4. Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B cells by ligation of CD20 vrith monoclonal antibodies. Blood 1998;91:1644-52.
5. Cardarelli PM, Quinn M, Buckman D, et al. Binding to CD20 by anti-B1 antibody or F(ab′)(2) is sufficient for induction of apoptosis in B-cell lines. Cancer Immunol Immunother 2002;51:15-24.
6. Tedder TF, Forsgren A, Boyd AW, Nadler LM, Schlossman SF. Antibodies reactive with the B1 molecule inhibit cell cycle progression but not activation of human B lymphocytes. Eur J Immunol 1986;16:881-7.
7. 131I]anti-B1 (anti-CD20) antibody. N Engl J Med 1993;329:459-65.
8. Kaminski MS, Gribbin T, Estes J, et al. I-131 anti-B1 antibody for previously untreated follicular lymphoma (FL): clinical and molecular remissions. Proc Am Soc Clin Oncol 1998;17:Suppl:2a. abstract.
9. Kaminski MS, Estes J, Zasadny KR, et al. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 2000;96:1259-66.
10. Vose JM, Wahl RL, Saleh M, et al. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2000;18:1316-23.
11. Kaminski MS, Zelenetz AD, Press OW, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2001;19:3918-28.
12. Horning SJ, Younes A, Lucas J, Podoloff D, Jain V. Rituximab treatment failures: tositumomab and iodine I 131 tositumomab [Bexxar] can produce meaningful durable responses. Blood 2002;100:Suppl:357a. abstract.
13. Coleman M, Kaminski MS, Knox SJ, Zelenetz AD, Vose JM. The BEXXAR therapeutic regimen (tositumomab and iodine I 131 tositumomab) produced durable complete remissions in heavily pretreated patients with non-Hodgkin's lymphoma (NHL), rituximab-relapsed refractory disease, and rituximab-naive disease. Blood 2003;102:Suppl: 29a. abstract.
14. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting - Airlie House, Virginia, November 1997. J Clin Oncol 1999;17:3835-49.
15. Kaminski MS, Zasadny KR, Francis IR, et al. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 1996;14:1974-81.
16. Goldsmith SJ, Kaminski M, Wahl R, et al. Dosimetry optimizes radiolabeled antibody dosing in patients with non-Hodgkin's lymphoma. Prog Proc Am Soc Clin Oncol 2001;20:Suppl:295a. abstract.
17. Zelenetz A, Wahl R, Kaminski M, Vose J, Kroll S, Leonard J. Individualized patient dosing prevents underdosing and overdosing of patients with non-Hodgkin's lymphoma. Prog Proc Am Soc Clin Oncol 2001;20:Suppl:287a. abstract.
18. Wahl RL. The clinical importance of dosimetryin radioimmunotherapy with tositumomab and iodine I 131 tositumomab. Semin Oncol 2003;30:Suppl 4:31-8.
19. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;457-81.
20. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-70.
21. Cox DR. Regression models and life-tables. J R Stat Soc [B] 1972;34:187-220.
22. Hainsworth JD, Litchy S, Burris HA III, et al. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol 2002;20:4261-7.
23. Colombat P, Salles G, Brousse N, et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001;97:101-6.
24. Dana BW, Dahlberg S, Nathwani BN, et al. Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy. J Clin Oncol 1993;11:644-51.
25. Fisher RJ, Dana BW, LeBlanc M, et al. Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: results of the Southwest Oncology Group randomized phase III study 8809. J Clin Oncol 2000;18:2010-6.
26. Solal-Celigny P, Lepage E, Brousse N, et al. Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. N Engl J Med 1993;329:1608-14.
27. Tsimberidou AM, McLaughlin P, Younes A, et al. Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma. Blood 2002;100:4351-7.
28. Czuczman MS, Grillo-Lopez AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999;17:268-76.
29. Czuczman M, Grillo-Lopez AJ, LoBuglio A, et al. Patients with low-grade NHL treated with rituximab + CHOP experience prolonged clinical and molecular remission. Blood 2003;102:Suppl:411a. abstract.
30. Johnson PW, Swinbank K, MacLennan S, et al. Variability of polymerase chain reaction detection of the bcl-2-IgH translocation in an international multicentre study. Ann Oncol 1999;10:1349-54.
31. Lopez-Guillermo A, Cabanillas F, McDonnell TI, et al. Correlation of bcl-2 rearrangement with clinical characteristics and outcome in indolent follicular lymphoma. Blood 1999;93:3081-7.
32. Press OW, Unger JM, Braziel RM, et al. A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911. Blood 2003;102:1606-12.
33. Leonard JP, Coleman M, Kostakoglu L, et al. Triple modality therapy for follicular low-grade lymphoma: initial treatment with fludarabine followed by Bexxar (tositumomab and iodine I 131 tositumomab). Blood 2001;98:Suppl:844a. abstract.
34. Nordoy T, Kolstad A, Tuck MK, Aaberge IS, Husebekk A, Kaminski MS. Radioimmunotherapy with iodine-131 tositumomab in patients with low-grade non-Hodgkin's B-cell lymphoma does not induce loss of acquired humoral immunity against common antigens. Clin Immunol 2001;100:40-8.
35. Armitage JO, Carbone PP, Connors JM, Levine A, Bennett JM, Kroll S. Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. J Clin Oncol 2003;21:897-906.